Immediately after occupational therapy (OT), people with multiple sclerosis may show small improvements in daily functioning and mental health-related quality of life (HR-QoL), but OT may have little ...

Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune ...

Many symptoms of MS are the same as those of other conditions. If you are concerned that you may have MS, make an appointment with your primary care provider. They will discuss your concerns and do a ...

CombiRx is a randomized clinical trial to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in ...

Change in Modified Fatigue Impact Scale scores did not differ between the groups. HealthDay News — Cognitive behavioral therapy (CBT), modafinil, and their combination are equally beneficial for ...

Hormone replacement therapy can be a way for women to prevent the inflammation that leads to disease. "There's some bone ...

An appreciation that aberrant immunological responses were important in multiple sclerosis led to the development and approval of interferon-β 1b. Glatiramer acetate and additional formulations of ...